Hereditary Spastic Paraplegia: Symptoms, Diagnosis and Spasticity Management

What is hereditary spastic paraplegia?

HSP describes more than 100 genetically and clinically diverse disorders. They share damage or dysfunction in the corticospinal tracts: very long nerve pathways that carry movement signals from the brain down the spinal cord. Because the longest fibres are particularly vulnerable, difficulties often appear first and most clearly in the legs.

The word hereditary refers to a genetic cause. It does not necessarily mean that several relatives are affected. A person may be the first recognised family member because a variant arose for the first time, because relatives have only subtle symptoms, because an altered gene is recessive, or because earlier generations were never diagnosed.

Spastic paraplegia refers to the pattern of increased muscle tone and weakness in both legs. It does not mean that everyone will become unable to walk. Some people remain independently mobile for decades; others need an orthosis, walking aid or wheelchair. The useful clinical question is not simply “How much spasticity is present?” but “How is the whole movement pattern affecting this person’s goals?” Our overview of what spasticity is explains why velocity-dependent resistance is only one part of the picture.

Pure and complex HSP

Clinicians often describe HSP as pure (uncomplicated) or complex (complicated). These are descriptions of the clinical pattern, not judgments about severity.

Pure HSP

In a pure pattern, the main problem is a gradually developing upper motor neuron syndrome in the legs. Possible features include:

• stiff or heavy legs, especially after rest or during faster walking;
• reduced foot clearance, toe catching, inward turning of a foot or a narrow-based gait;
• leg weakness, often felt most during stairs, slopes or prolonged walking;
• brisk reflexes, ankle clonus and an extensor plantar response;
• urinary urgency or frequency;
• reduced vibration sensation in the feet; and
• fatigue, pain, cramps or spasms, which may fluctuate even when the underlying condition changes slowly.

Complex HSP

In complex HSP, leg spasticity occurs with other neurological or systemic features. Depending on the genetic subtype, these can include ataxia, peripheral neuropathy, seizures, cognitive or developmental differences, speech or swallowing difficulty, optic or retinal disease, hearing loss, movement disorders, muscle wasting or changes visible on brain MRI. No individual is expected to have all of these features.

Knowing whether the pattern is pure or complex helps guide testing, but it is not always obvious at the first appointment. Features can emerge over time, and the same gene can produce different effects in different relatives. This variability is one reason that a careful neurological history and examination remain important even in the era of broad genetic panels.

How does HSP usually progress?

Onset can occur in early childhood or late adulthood. Progression is usually gradual, but it is not necessarily smooth: growth, illness, pain, poor sleep, reduced activity and changes in equipment can temporarily make function feel worse. Some forms beginning in childhood may remain relatively stable after an initial period, while others progress more noticeably. A gene name alone rarely predicts an exact future for one person.

A sudden change over hours or days is not typical of a slowly progressive inherited condition and should not automatically be attributed to HSP. Infection, injury, constipation, urinary problems, medication effects or a new neurological problem may be responsible. See our guide to sudden worsening of spasticity for common triggers and warning signs.

Genes and inheritance: why there is no single family-risk figure

HSP may follow autosomal dominant, autosomal recessive, X-linked or mitochondrial inheritance. A change in one gene copy can cause some dominant forms; recessive forms usually require disease-causing variants in both copies of the same gene. X-linked and mitochondrial conditions follow different family patterns. De novo variants and reduced penetrance add further complexity.

That means no universal “50% risk” or “one in four risk” applies to every family. A meaningful estimate depends on the exact gene, the specific variant, how it is classified, the inheritance pattern and which family members have been tested. Genetic counselling can help a family understand what is known, what remains uncertain and whether testing would change medical or reproductive decisions.

When possible, testing usually begins with a person who has symptoms. Testing an unaffected relative without first identifying the familial variant may be uninformative. A variant of uncertain significance is not the same as a confirmed diagnosis and should not be used alone to label relatives or make irreversible decisions.

How HSP is diagnosed

There is no single bedside test that proves HSP. Diagnosis combines the clinical pattern, family history, exclusion of treatable or acquired causes and, when possible, a molecular genetic result. The process may involve a neurologist, neurogeneticist or clinical geneticist, a rehabilitation specialist and allied health professionals.

1. History and neurological examination

The clinician asks when walking changed, how symptoms have progressed, whether bladder, sensory, balance, vision, hearing, learning or seizure problems are present, and whether relatives have similar signs. Examination looks at strength, tone, reflexes, coordination, sensation and gait. It also distinguishes dynamic overactivity from weakness, poor selective motor control and a fixed contracture. Our guide to spasticity assessment describes this broader approach.

2. Looking for mimics and treatable causes

Brain and spinal-cord MRI may be used to exclude compression, inflammation and other structural disease, and sometimes shows clues to a particular HSP subtype. Blood tests, and occasionally cerebrospinal-fluid analysis, nerve-conduction studies, eye tests or metabolic investigations, are selected according to age, tempo and associated findings. Deficiencies, infections, inflammatory disease and metabolic disorders can produce a spastic paraparesis and may require very different treatment.

3. Genetic testing

Because HSP is genetically heterogeneous, clinicians often use a multigene panel or exome/genome-based testing rather than testing one gene at a time. The laboratory may also need methods that detect deletions, duplications, repeat expansions or mitochondrial variants; not every test detects every type of change.

A positive result is most useful when the variant is classified as pathogenic or likely pathogenic and fits the person’s clinical pattern. A negative test does not exclude HSP: the relevant gene may not yet be known, the causal change may be difficult for the chosen method to detect, or the diagnosis may need to be reconsidered. Results should be interpreted in clinical context rather than read as a stand-alone answer.

Measuring what matters

Muscle tone scales can document part of the examination, but they do not capture endurance, balance, confidence, falls or participation. A useful baseline may include walking speed and distance, timed transfers, stair performance, foot clearance, range of motion, strength, bladder symptoms, pain, fatigue and the amount of assistance required in daily life. Read more about the Modified Ashworth Scale, Tardieu Scale and functional assessment.

Goals should be concrete and personal: walking safely to work, reducing toe catching, sleeping with fewer spasms, completing a transfer with less help, maintaining joint range, or conserving energy for family life. Repeating the same measures helps the team judge whether an intervention is delivering a meaningful benefit.

Treatment and rehabilitation for HSP

For most forms of HSP, current care is symptomatic and supportive; there is not yet a treatment that reliably reverses the underlying genetic disorder. This does not mean that nothing can be done. A coordinated plan can improve safety, comfort, efficiency and independence, and can prevent avoidable secondary problems.

Physiotherapy and physical activity

Physiotherapy may address joint range, strength, selective control, balance, aerobic fitness and task practice. Stretching can help maintain comfort and range when it is appropriately dosed, but it should not replace strengthening or functional training. Activity plans need to be sustainable: excessive fatigue or pain after every session is a signal to adjust intensity, not proof that more effort is always better. Our rehabilitation guide discusses how therapy fits with real-life goals.

Gait aids, orthoses and mobility devices

An ankle-foot orthosis may improve foot clearance or ankle stability for some people. A cane, crutches, walker or wheelchair can reduce falls and energy cost; using a wheelchair for long distances does not cancel the benefits of walking for shorter tasks. Equipment should be assessed and reviewed as needs change. The pattern described as “spastic gait” can also reflect weakness or contracture, so device selection should follow a functional gait assessment rather than a label alone. See spastic gait and lower-limb spasticity.

Medicines and focal treatment

Oral medicines such as baclofen or tizanidine may reduce troublesome generalized spasticity, but possible sleepiness, dizziness and weakness matter—especially when some tone helps a person stand or transfer. Doses are normally started and adjusted cautiously. Botulinum toxin may be considered for a focal pattern, for example when calf or hip-adductor overactivity interferes with a defined goal. It works best as part of a plan that includes therapy, stretching, positioning or orthotic review.

For severe generalized spasticity that has not responded adequately to other approaches, a specialist team may consider intrathecal baclofen after careful testing. Orthopaedic procedures are directed mainly at fixed contracture or deformity rather than the genetic disease itself. Any escalation should begin with clear spasticity treatment goals and a plan to measure both benefit and unwanted loss of function.

Other symptoms deserve treatment too

Bladder urgency, constipation, pain, fatigue, mood, sleep, swallowing or speech difficulties can affect quality of life as much as walking. Complex HSP may require input from urology, speech and language therapy, occupational therapy, psychology, ophthalmology or other specialties. Treatment should address the person, not only the leg tone.

Living with HSP: practical planning

• Track function, not every sensation. Note meaningful changes such as falls, distance walked, recovery time or new assistance needs.
• Review footwear and equipment. A worn orthosis, poorly fitting shoe or changed walking aid can increase effort and skin risk.
• Plan energy. Alternate demanding and lighter tasks, use mobility equipment strategically and preserve capacity for valued activities.
• Prepare for appointments. Bring the genetic report, medication list, family history and a short video of difficult walking situations if safe to record.
• Discuss work, school and driving early. Occupational therapy and reasonable adjustments can reduce physical load and improve access.
• Offer relatives information without pressure. Predictive testing is a personal decision best made with genetic counselling.

When to seek prompt medical assessment

Arrange timely review for a clear acceleration in symptoms, repeated falls, new bladder problems, increasing pain, swallowing difficulty or a substantial change in walking. Seek urgent medical care for sudden weakness, new loss of sensation, severe back pain with bladder or bowel change, fever with marked deterioration, a new seizure, acute confusion or stroke-like symptoms. These are not changes to simply “watch because it is HSP.”

Questions people often ask

Does HSP always lead to wheelchair use?

No. Mobility outcomes vary greatly between subtypes and individuals. Some people never need a wheelchair; others use one for distance, safety or energy conservation. A mobility aid is a tool for participation, not a measure of failure.

Can HSP skip a generation?

It can appear to do so because of reduced penetrance, very mild symptoms, recessive inheritance or incomplete family information. The explanation depends on the molecular diagnosis and family tree.

Can exercise make HSP worse?

Appropriately prescribed strengthening and aerobic activity are generally used to support function and health. The programme should be adapted if it causes prolonged pain, unsafe fatigue or loss of function. A therapist can help distinguish normal training effort from an unsuitable dose.

Is a genetic result enough to choose treatment?

Usually not. The result may clarify diagnosis, inheritance and surveillance, but day-to-day treatment is still guided by symptoms, examination, function and personal goals.